We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 02, 2021

Comparison of Duration of Response vs Conventional Response Rates and PFS as Efficacy Endpoints in Simulated Immuno-Oncology Clinical Trials

JAMA Network Open

 

Additional Info

JAMA Network Open
Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-Oncology Clinical Trials
JAMA Netw Open 2021 May 03;4(5)e218175, C Hu, M Wang, C Wu, H Zhou, C Chen, S Diede

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading